AR065095A1 - COMPUESTO DE ARIL-OXO-DIAZAESPIRO, INTERMEDIARIO PARA SU SíNTESIS, USO DEL MISMO PARA PREPARAR UN MEDICAMENTO PARA EL TRATAMIENTO DE UN TRASTORNO MEDIADO POR GLYT1, COMPOSICION FARMACEUTICA Y ASOCIACION QUE LO COMPRENDEN. - Google Patents
COMPUESTO DE ARIL-OXO-DIAZAESPIRO, INTERMEDIARIO PARA SU SíNTESIS, USO DEL MISMO PARA PREPARAR UN MEDICAMENTO PARA EL TRATAMIENTO DE UN TRASTORNO MEDIADO POR GLYT1, COMPOSICION FARMACEUTICA Y ASOCIACION QUE LO COMPRENDEN.Info
- Publication number
- AR065095A1 AR065095A1 ARP080100379A ARP080100379A AR065095A1 AR 065095 A1 AR065095 A1 AR 065095A1 AR P080100379 A ARP080100379 A AR P080100379A AR P080100379 A ARP080100379 A AR P080100379A AR 065095 A1 AR065095 A1 AR 065095A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- hydrogen
- cycloalkyl
- nitrogen atom
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000015572 biosynthetic process Effects 0.000 title abstract 3
- 238000003786 synthesis reaction Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 32
- 239000001257 hydrogen Substances 0.000 abstract 17
- 229910052739 hydrogen Inorganic materials 0.000 abstract 17
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 17
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 5
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 239000011737 fluorine Substances 0.000 abstract 3
- 101100134929 Gallus gallus COR9 gene Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 150000002576 ketones Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuesto derivado del aril-oxo-diazaespiro amidas o cetonas de formula o una sal del mismo en el que: R1 se selecciona de: hidrogeno, alquilo C1-4, alcoxi C1-4, halo, haloalquilo C1-4, haloalcoxi C1-4 [alquil C1-4]tio, cicloalquilo C3-6, [cicloalquil C3-6]alquilo C1-4,sulfonilo, [alcoxi C1-4]alquilo C1-4, ciano y CONRaRb (en el cual Ra y Rb se seleccionan independientemente de H y alquilo C1-4 o Ra y Rb, junto con el átomo de nitrogeno al que están unidos, forman un anillo de 4 a 7 miembros; R2 se selecciona de: hidrogeno, alquilo C1-4, alcoxi C1-4, halo, haloalquilo C1-4, haloalxcoxi C1-4, [alquil C1-4]tio, cicloalquilo C3-6, [cicloalquil] C3-6, (cicloalquil C3-6]alquilo C1-4, [alquil C1-4]sulfonilo, [alcoxi C1-4]alquilo C1- 4, ciano CONRcRd (en el que Rc y Rd se seleccionan independientemente de H y alquilo C1-4 o Rc y Rd, junto con el átomo de nitrogeno al que están unidos, forman un anillo de 4 a 7 miembros; R3 selecciona de hidrogeno, alquilo C1-4, alcoxi C1-4, halo, haloalquilo C1-4, haloalcoxi C1-4, [alquil C1-4]tio, cicloalquilo C3-6, (cicloalquil C3-6)alquilo C1-4, (alquilo C1-4]sulfonilo, [alcoxi C1-4]alquilo C1-4, ciano y CONReRt (en el que Re y Rf se seleccionan independientemente de H y alquilo C1- 4 o Re y Rf, junto con el átomo de nitrogeno al que están unidos, forman un anillo de 4 a 7 miembros); o R2 y R3 forman juntos un grupo seleccionado de -O-CH2-O- y -O-CH2-CH2-O-; R4 se selecciona de: hidrogeno, alquilo C1-4; halo, haloalquilo C1-4, haloalcoxi C1-4, [alquil C1-4]tio, cicloalquilo C3-6, [cicloalquil C3-6]alquilo C1-4, (alquil C1-4 sulfonilo, (alcoxi C1-4)alquilo C1-4, ciano y CONRgRh (en el que Rg y Rh se seleccionan indecentemente de H y alquilo C1-4 o Rg y Rh, junto con el átomo de nitrogeno al que están unidos, forman un anillo de 4 a 7 miembros); R5 se selecciona de: hidrogeno, cloro, fluor, alquilo C1-4 y CF3; R6 se selecciona de: (alcoxi C1-4) alquilo (alquil C1-4)sulfonilo, (alquil C1-4)tio, COR9 (en el que R9 es hidrogeno o alquilo C1-4);CONRiRj (en el que Ri y Rj se seleccionan independientemente de hidrogeno y alquilo C1-4 o, junto con el átomo de nitrogeno al que están unidos forman un anillo de 4, 5 o 6) y CHRkRlRm (en el que Rk es hidrogeno o alquilo C1-4 y Rl y Rm se seleccionan independientemente de hidrogeno y alquilo C1-4 o Rl y Rm, junto con el átomo de nitrogeno al que están unidos forman un anillo de 4, 5 o 6 miembros); R15 es hidrogeno o fluor; R7 se selecciona de: hidrogeno, alquilo C1- 4, alcoxi C1-4, haloalquilo C1-4, haloalcoxi C1-4 halo, ciano, (alcoxi C1-4) alcoxi C1-4 y (alcoxi C1-4)alquilo C1-4; R8 se selecciona de hidrogeno y metilo y m se selecciona de 0, 1 y 2. Su uso para la fabricacion de un medicamento util para el tratamiento de un trastorno mediado por GlyTl, tal como esquizofrenia, demencia y trastorno por falta de atencion. Composicion farmacéutica y asociacion con uno o más agentes terapéuticos que lo comprenden. Compuesto intermediario para su síntesis. Reivindicacion 12: Un compuesto intermediario en la síntesis del compuesto de la formula (1) de la reivindicacion 1, caracterizado porque es de formula (II) o una sal del mismo en el que R6 se selecciona de: (alcoxi C1-4)alquilo C1-4, (alquil C1-4)sulfonilo, (alquil C1-4)tio, COR9 (en el que R9 es hidrogeno o alquilo C1-4), CONRiRj (en el que Ri y Rj se seleccionan independientemente de hidrogeno o alquilo C1-4 o, junto con el átomo de nitrogeno al que están unidos forman un anillo de 4, 5 o 6 miembros): R15 es hidrogeno o fluor; R7 se selecciona de: hidrogeno, alquilo C1-4, alcoxi C1-4, haloalquilo C1-4, haloalcoxi C1-4, halo, ciano, (alcoxi C1-4)alcoxi C1-4 y (alcoxi C1-4)alquilo C1-4; R8 se selecciona de hidrogeno y metilo y m se selecciona de 0.1 y 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0701984A GB0701984D0 (en) | 2007-02-01 | 2007-02-01 | Compounds |
| GB0716990A GB0716990D0 (en) | 2007-08-31 | 2007-08-31 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065095A1 true AR065095A1 (es) | 2009-05-13 |
Family
ID=39267938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100379A AR065095A1 (es) | 2007-02-01 | 2008-01-30 | COMPUESTO DE ARIL-OXO-DIAZAESPIRO, INTERMEDIARIO PARA SU SíNTESIS, USO DEL MISMO PARA PREPARAR UN MEDICAMENTO PARA EL TRATAMIENTO DE UN TRASTORNO MEDIADO POR GLYT1, COMPOSICION FARMACEUTICA Y ASOCIACION QUE LO COMPRENDEN. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100113545A1 (es) |
| EP (1) | EP2121622A1 (es) |
| JP (1) | JP2010517959A (es) |
| AR (1) | AR065095A1 (es) |
| CL (1) | CL2008000302A1 (es) |
| TW (1) | TW200846328A (es) |
| WO (1) | WO2008092872A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090124651A1 (en) | 2007-08-31 | 2009-05-14 | H. Lundbeck A/S | Catecholamine derivatives and prodrugs thereof |
| AR068388A1 (es) * | 2007-09-11 | 2009-11-11 | Glaxo Group Ltd | Compuesto derivado de imidazol - fenil-oxo-1,4- diazaespiro arilo, su uso para preparar un medicamento, composicion farmaceutica y combinacion que lo comprenden |
| GB0814990D0 (en) * | 2008-08-15 | 2008-09-24 | Glaxo Group Ltd | Compounds |
| US8153653B2 (en) * | 2010-06-22 | 2012-04-10 | Hoffmann-La Roche Inc. | Amido-tropane derivatives |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3262472A (en) * | 1964-05-08 | 1966-07-26 | Black & Decker Mfg Co | Depth and bevel adjustment means for portable power-driven saw |
| US3787973A (en) * | 1972-12-15 | 1974-01-29 | Skil Corp | Safety retracting mechanism for the lower guard of a portable saw |
| US3882598A (en) * | 1974-06-17 | 1975-05-13 | Johns Manville | Dust control cutting assembly for cutting sheet material |
| US4241505A (en) * | 1979-05-21 | 1980-12-30 | Johns-Manville Corporation | Dust shroud for portable circular saw |
| US5010651A (en) * | 1990-07-10 | 1991-04-30 | Skil Corporation | Portable circular saw |
| US4999916A (en) * | 1990-08-17 | 1991-03-19 | Ryobi Motor Products Corp. | Circular saw base angle adjustment mechanism |
| US5074044A (en) * | 1991-04-26 | 1991-12-24 | Duncan C Warren | Dust disposal attachment for a rotary element of a power tool |
| DE4124233A1 (de) * | 1991-07-22 | 1993-01-28 | Bosch Gmbh Robert | Handkreissaege |
| GB9225441D0 (en) * | 1992-12-04 | 1993-01-27 | Black & Decker Inc | A saw |
| DE4300033B4 (de) * | 1993-01-02 | 2005-02-24 | Robert Bosch Gmbh | Handkreissäge mit Gehrungswinkel-Einstellvorrichtung |
| US5327649A (en) * | 1993-02-11 | 1994-07-12 | Skinner Christopher L | Circular saw with dust collector |
| US20040261592A1 (en) * | 1993-05-18 | 2004-12-30 | Rexon Industrial Corp., Ltd. | Laser guiding device for table saw machine |
| US5461790A (en) * | 1994-02-16 | 1995-10-31 | Olstowski; Franek | Circular saws with laser guides for more precise movement during cutting |
| US5774992A (en) * | 1997-02-26 | 1998-07-07 | Lindenmuth; Steve D. | Dust shroud for power saw |
| US6219922B1 (en) * | 1997-06-04 | 2001-04-24 | Black & Decker, Inc. | Nozzle assembly for a power tool |
| US6263584B1 (en) * | 1997-08-08 | 2001-07-24 | Barry S. Owens | Alignment apparatus and method of using same |
| US6447379B1 (en) * | 2000-03-31 | 2002-09-10 | Speedfam-Ipec Corporation | Carrier including a multi-volume diaphragm for polishing a semiconductor wafer and a method therefor |
| US6557261B1 (en) * | 2001-08-21 | 2003-05-06 | John P. Buser | Dust-capturing adaptor for a saw |
| US6827640B2 (en) * | 2002-03-01 | 2004-12-07 | S&G Company, Llc | Portable dust collection system |
| ES2297502T3 (es) * | 2003-10-23 | 2008-05-01 | F. Hoffmann-La Roche Ag | Derivados de triaza-espiropiperidinas para uso como inhibidores de glyt-1 en el tratamiento de trastornos neurologicos y neuropsiquiatricos. |
| US7328512B2 (en) * | 2004-09-14 | 2008-02-12 | Martin Charles B | Self-contained vacuum saw |
| JP2009503006A (ja) * | 2005-08-02 | 2009-01-29 | グラクソ グループ リミテッド | ＧｌｙＴ１トランスポーター阻害剤ならびに神経および神経精神障害の治療におけるその使用 |
| JP2009530247A (ja) * | 2006-03-16 | 2009-08-27 | グラクソ グループ リミテッド | Ｎ−フェニル−２−オキソ−１，４−ジアザスピロ［４．５］デカ−３−エン−１−イルアセトアミド誘導体およびグリシン輸送体阻害剤としてのそれらの使用 |
| US20090062360A1 (en) * | 2006-03-16 | 2009-03-05 | Steven Coulton | Compounds Which Inhibit the Glycine Transporter and Uses Thereof |
| GB0607398D0 (en) * | 2006-04-12 | 2006-05-24 | Glaxo Group Ltd | Compounds |
| WO2010124293A1 (en) * | 2009-04-24 | 2010-10-28 | Martin Charles B | Portable cutting device with on-board debris collection |
-
2008
- 2008-01-30 JP JP2009547671A patent/JP2010517959A/ja active Pending
- 2008-01-30 WO PCT/EP2008/051077 patent/WO2008092872A1/en active Application Filing
- 2008-01-30 EP EP08708394A patent/EP2121622A1/en not_active Withdrawn
- 2008-01-30 US US12/524,593 patent/US20100113545A1/en not_active Abandoned
- 2008-01-30 TW TW097103386A patent/TW200846328A/zh unknown
- 2008-01-30 AR ARP080100379A patent/AR065095A1/es unknown
- 2008-01-31 CL CL200800302A patent/CL2008000302A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2008000302A1 (es) | 2008-08-08 |
| TW200846328A (en) | 2008-12-01 |
| US20100113545A1 (en) | 2010-05-06 |
| WO2008092872A1 (en) | 2008-08-07 |
| JP2010517959A (ja) | 2010-05-27 |
| EP2121622A1 (en) | 2009-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR071856A1 (es) | Derivados de indazoles sustituidos con fenilo o piridinilo, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides. | |
| AR071385A1 (es) | Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia. | |
| AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
| AR081653A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR055554A1 (es) | Compuestos piridinicos, composicion farmaceutica y uso de los compuestos para preparar medicamentos | |
| CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| ES2770058T3 (es) | Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante | |
| AR066502A1 (es) | Compuestos amino- heterociclicos | |
| PE20212023A1 (es) | Compuestos, composiciones y metodos | |
| AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| AR076002A1 (es) | Derivados imidazolicos heterociclicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. | |
| AR074966A1 (es) | Compuestos amino-heterociclicos | |
| JO3215B1 (ar) | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy | |
| MX2008012404A (es) | Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g. | |
| AR058006A1 (es) | Mimeticos de glucocorticoides, composiciones farmaceiticas y usos de los mismos | |
| AR083339A1 (es) | Compuestos de quinazolina como bloqueadores de los canales de sodio | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| CA2587800A1 (en) | Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| RS54288B1 (en) | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR098147A1 (es) | Composiciones herbicidas que contienen amidas de ácido n-(1,3,4-oxadiazol-2-il)arilcarboxílico | |
| PE20161432A1 (es) | Compuestos y composiciones para inducir condrogenesis | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |